Skip to content

Study · Not a test of the peptide alone · 2026

1 result

Nf2 orchestrates β-arrestin2-biased PTH1R signaling to couple bone mass with skeletal integrity.

Liao J, He Y, Zhang C, Qian Q, Huang Y, Zhang Q, Shen P, Zhou C, Wu M, Chen G

Proceedings of the National Academy of Sciences of the United States of America10 Jun 2026Cited by 2 (Europe PMC)

PMID42268882 (opens in a new tab)PMCIDPMC13273255 (opens in a new tab)DOI10.1073/pnas.2524671123 (opens in a new tab)PepBankPUB-42268882
Read at sourcePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Abaloparatide (Tymlos).

  1. 01AnimalNot a test of Abaloparatide (Tymlos) aloneAnimal study (in vivo)Mechanism

    Nf2-deficient mice exhibited bone changes similar to those induced by abaloparatide.

    In plain wordsIn mice, Nf2 loss produced bone changes similar to those induced by abaloparatide.

    Peptide
    Abaloparatide (Tymlos)
    Outcome
    Not applicableBone phenotype resemblance
    Study

    mousen: not reported in source

    Nf2-deficient mice
    Comparator
    Abaloparatide-induced bone changes
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    Consequently, Nf2-deficient mice exhibited bone changes similar to those induced by the PTH1R agonist abaloparatide.

    In this study, Abaloparatide (Tymlos) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Abaloparatide (Tymlos).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.